1. Home /
  2. Drug Approvals

Drug Approvals

Gilead Has Become and Will Be a Volatile Name

I would consider any entry a trade, and not an investment.

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Any modest intraday dip is probably a buying opportunity.

Jim Cramer: Did You Ever Think That 80% of Our Drugs Originated in China?

Did you ever think that could be allowed? That our government let that happen? No one seemed to think about it until now. The answer, like the coronavirus, is we knew.

The Wisdom of Taking Profits in Small Biotech Stocks Upon FDA Drug Approval

There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.

2 Healthcare Stocks That Look Like Bargains Relative to Their Growth Prospects

Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.

2 Small Biotechs Face Crossroads Years in 2020

Dynavax Technologies and Omeros Corp. have tested shareholders' patience over time and again are at inflection points.

Jim Cramer: Panic Has Not Been Contained in This Market

I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.

This Drugmaking Dividend Stock Due for Shot in the Arm

Gilead offers a nearly 4% yield and looks ready to return to growth.

3 Languishing Small-Caps That Should Perk Up in 2020

Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.

Two Biotech Plays to Consider From the Long Side

Let's review the charts of Allakos and Global Blood Therapeutics.